NCI’s Consumer Liaison Group Chooses Four Areas of Concern

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

The co-chairs are M. Venus Gines, a breast-cancer survivor from Lithonia, Ga, active in community work with the American Cancer Society; Susan A. Leigh of Tucson, Ariz, a survivor of Hodgkin’s disease, breast cancer, and bladder cancer, and active in the National Coalition for Cancer Survivorship and the Oncology Nursing Society; and Daniel M. Moore, Jr., a prostate cancer survivor from Decatur, Ill, who started the Central Illinois US TOO! prostate cancer support group.

The consumer group’s four areas of immediate concern are communications and immediate access to reliable cancer information; informed consent, including making forms more understandable; patient consumer issues and population and genetics studies; and ways to identify additional consumer representatives for NCI committees and groups.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content